Proteomics approaches to long COVID: status and outlooks

Xiao Liang; Yingrui Wang; Tiannan Guo

doi:10.1093/lifemedi/lnad023

PDF(380 KB)

Life Medicine ›› 2023, Vol. 2 ›› Issue (3) : 4. DOI: 10.1093/lifemedi/lnad023

Research Highlight

Proteomics approaches to long COVID: status and outlooks

Xiao Liang¹^,²^,³^,⁴ ,
Yingrui Wang¹^,²^,³^,⁴ ,
Tiannan Guo¹^,²^,³^,⁴

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Xiao Liang, Yingrui Wang, Tiannan Guo. Proteomics approaches to long COVID: status and outlooks. Life Medicine, 2023, 2(3): 4 https://doi.org/10.1093/lifemedi/lnad023

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Network Open 2021;4:e2128568. CrossRef Google scholar

[2]	Soriano JB, Murthy S, Marshall JC, et al; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022;22:e102–7. CrossRef Google scholar

[3]	Lu T, Wang Y, Guo T. Multi-omics in COVID-19: seeing the unseen but overlooked in the clinic. Cell Rep Med 2022;3:100580. CrossRef Google scholar

[4]	Chen Y, Zhang N, Zhang J, et al. Immune response pattern across the asymptomatic, symptomatic and convalescent periods of COVID-19. Biochim Biophys Acta Proteins Proteom 2022;1870:140736. CrossRef Google scholar

[5]	Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol 2021;20:172. CrossRef Google scholar

[6]	Captur G, Moon JC, Topriceanu C-C, et al; UK COVIDsortium Investigators. Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. EBioMedicine 2022;85:104293. CrossRef Google scholar

[7]	Zhao J, Schank M, Wang L et al. Plasma biomarkers for systemic inflammation in COVID-19 survivors. Proteomics Clin Appl 2022;16:e2200031. CrossRef Google scholar

[8]	Vijayakumar B, Boustani K, Ogger PP, et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity 2022;55:542–556.e5. CrossRef Google scholar

[9]	Su Y, Yuan D, Chen DG, et al; ISB-Swedish COVID-19 Biobanking Unit. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022;185:881–895.e20.

[10]	Shen B, Yi X, Sun Y, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell 2020;182:59–72.e15. CrossRef Google scholar